Rainbow Seed Fund News

Cambridge, UK, 11 September 2018 – Crescendo Biologics Ltd (Crescendo), the drug developer of novel, targeted T-cell enhancing therapeutics, today announces that Pavel Pisa, MD, PhD, has been appointed as Chief Medical Officer of the Company with immediate effect. Pavel Pisa is the former Head of Translational Medicine at Roche and Genentech and has led […]

read more

Cambridge, UK: 2 February 2016 – Crescendo Biologics Limited (Crescendo), the drug discovery and developer of Humabody™ VH therapeutics, today announced the appointment of Dr Barbara Fleck as Head of Intellectual Property. Barbara Fleck, a European and Chartered Patent Attorney, has over 13 years’ experience of Intellectual Property issues in the bio therapeutics field, including […]

read more

Antibody veteran joins new CEO as Crescendo redirects strategy to Oncology focus Cambridge, UK: 17 November 2015 – Crescendo Biologics Limited (Crescendo), the drug discovery and developer of Humabody™ VH therapeutics, today announced the appointment of Dr. Kevin Johnson as non-executive Chairman of the Board of Directors. The appointment is effective immediately. Dr. Johnson brings […]

read more

1 2 3